Ginsenoside Rg6
CAS No. 147419-93-0
Ginsenoside Rg6( —— )
Catalog No. M29052 CAS No. 147419-93-0
Ginsenoside Rg6 inhibits the proliferation and induces apoptosis of human lymphoma JK cells
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 254 | Get Quote |
|
| 10MG | 379 | Get Quote |
|
| 25MG | 647 | Get Quote |
|
| 50MG | 897 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGinsenoside Rg6
-
NoteResearch use only, not for human use.
-
Brief DescriptionGinsenoside Rg6 inhibits the proliferation and induces apoptosis of human lymphoma JK cells
-
DescriptionGinsenoside Rg6 inhibits the proliferation and induces apoptosis of human lymphoma JK cells(In Vitro):Ginsenoside Rg6 may inhibit the proliferation and induce apoptosis of human lymphoma JK cells through mitochondrial dysfunction and increased Bax expression and decreased Bcl-2 expression. In addition, ginsenoside Rg6 can also inhibit the transcriptional activity of NF-κB induced by TNF-α in SK-Hep1 cells with IC50 of 25uM.
-
In VitroGinsenoside Rg6 inhibits TNF-α-induced NF-κB transcriptional activity with an IC50 of 25.12±1.04 μM in SK-Hep1 cells, consistent with the data from HepG2 cells. Ginsenoside Rg6 exhibits obvious anti-proliferative and apoptosis-inducing effects when it is applied to JK cells in vitro. Ginsenoside Rg6 blocks S arrest in the cell cycle. CCK-8 method shows that after Ginsenoside Rg6 is used, several groups with different concentrations obviously inhibits JK cell proliferation in human lymphocytoma, with evident dose dependency. Based on IC50, the median inhibitory concentration of Ginsenoside Rg6 is 83.08 μM.
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number147419-93-0
-
Formula Weight767.01
-
Molecular FormulaC42H70O12
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (130.38 mM)
-
SMILES[H][C@@]12[C@H](CC[C@@]1(C)[C@]1(C)C[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)C3C(C)(C)[C@H](O)CC[C@]3(C)[C@@]1([H])C[C@@H]2O)C(=C)CCC=C(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
RAPTA-C
RAPTA-C induces EAC cell cycle arrest and apoptosis via the mitochondrial and p53-JNK pathways, and can be used in the study of breast and ovarian cancer.
-
LYN-1604 dihydrochlo...
LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.
-
EC359
EC359 is a potent and selective inhibitor of leukemia inhibitory factor receptor (LIFR), a potent inhibitor with anticancer activity, blocks LIF/LIFR interaction, and can be used in the study of leukemia and endometrial cancer.
Cart
sales@molnova.com